InveniAI Appoints Industry Leader Dr. Salvatore Alesci as Chief Scientific Officer to Advance AI-Powered Portfolio of Assets Targeting Dysregulation of the Gut-Brain Axis
May 11, 2021 08:10 ET | InveniAI LLC
Pipeline to include new chemical entities as well as re-innovated drugs, all targeting dysregulation of the gut-brain axis and inflammasome pathways for chronic inflammatory diseasesDr. Alesci’s...
InveniAI and Shionogi Enter AI-Powered Multi-Target Drug Discovery Collaboration
April 27, 2021 08:10 ET | InveniAI LLC
Teams will work together by leveraging InveniAI's technology to identify, evaluate, and optimize novel targets for drug discoveryShionogi will synthesize and develop compounds for targets identified...
InveniAI and Kyowa Kirin Enter AI-Powered Novel Target Discovery Collaboration
December 09, 2020 08:10 ET | InveniAI
Expansion of existing collaboration will leverage InveniAI® technology to identify, evaluate, and optimize novel targets for Kyowa Kirin’s antibody technologyKyowa Kirin will select multiple programs...
InveniAI and PRISM BioLab Initiate a Collaboration for the Development of Therapeutic Candidates for Treatment of Gut-Related Diseases Impacted by the Gut-Brain Axis and Inflammasome Activation Pathways
September 09, 2020 08:10 ET | InveniAI
Partnership with Japan-based PRISM BioLab will enable the synthesis and development of proprietary therapeutic small-molecule candidates against molecular targets identified by InveniAI’s AI platform...
Tackling Tuberculosis with AI: Novel TBMeld® Platform to Transform Research in the Prevention and Treatment of Tuberculosis
July 31, 2020 08:00 ET | InveniAI
-InveniAI announces partnership with the Mueller Health Foundation (MHF) to create a first of its kind AI-driven platform to be used for the discovery, tracking, and evaluation of 1) novel TB...
InveniAI Enters Strategic Artificial Intelligence (AI) and Machine Learning (ML) Focused Collaboration with GlaxoSmithKline Consumer Healthcare
July 29, 2020 08:30 ET | InveniAI
Three-year strategic collaboration to leverage InveniAI’s AI- and ML-powered Platform, AlphaMeld® after a successful proof-of-value collaborationAlphaMeld® will capture consumer-specific innovation...
InveniAI Announces Strategic Partnership with TB Alliance to Advance the Development of Transformative Therapies for Tuberculosis
June 02, 2020 08:00 ET | InveniAI
GUILDFORD, Conn., June 02, 2020 (GLOBE NEWSWIRE) -- InveniAI® LLC, a global leader pioneering the application of artificial intelligence (AI) and machine learning (ML) to transform innovation across...
InveniAI Introduces New Products to its AI-Powered Pharmaceutical Drug Discovery and Development Suite
November 06, 2019 08:00 ET | InveniAI
GUILFORD, Conn., Nov. 06, 2019 (GLOBE NEWSWIRE) -- InveniAI® Corporation, a global leader pioneering the application of artificial intelligence (AI) and machine learning (ML) to transform innovation...
InveniAI Launches Suite of Products Powered by AlphaMeld™, an Artificial Intelligence Platform, to Enable Robust Decision Making for Multiple Stakeholders in the Life Sciences
September 17, 2019 08:30 ET | InveniAI
- CIMeld™, an AlphaMeld™ powered product for competitive/business intelligence, is set to launch at PharmaCI USA 2019 - Tailored suite of products to address high value questions accelerating...
InveniAI Appoints Industry Veteran Dr. Amit Agrawal to Board of Directors and Expands its Operations into the EU
July 02, 2019 08:31 ET | InveniAI
 Dr. Agrawal, a biopharma Strategy and R&D leader, brings scientific and technology expertise to a world-class board of directors at InveniAI. InveniAI establishes presence in Basel, Switzerland...